Small Cell Lung Cancer That Spread to the Ear Canal
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Small Cell Lung Cancer
- Sex
- male
- Spread to
- external auditory canal, middle ear, pancreas, bone
- Treatment
- chemotherapy
- Outcome
- In Memory
Treatment course, step by step
- Received carboplatin and etoposide chemotherapy.
- Zoledronic acid was given for bone metastases.
What happened, in summary
A 77-year-old man developed several weeks of left-sided hearing loss, ear pain, and a red mass filling the external auditory canal. Imaging also found a mass in the right upper lung, a pancreatic lesion, and disease involving bone. Biopsies from the ear-canal, lung, and pancreatic lesions confirmed small cell lung cancer arising from the lung, making this a Stage IV presentation.
He received carboplatin and etoposide chemotherapy, with zoledronic acid for bone metastases. The treatment reduced the metastatic tumors, including the lesions in the external auditory canal and middle ear. As the tumor shrank, his hearing improved enough that conversations became easier to understand, and his ear pain improved enough for opioid pain treatment to be stopped.
Despite this initial response, the cancer remained advanced. He died 15 months after diagnosis. At autopsy, the external auditory canal lesions had resolved grossly, showing that this unusual metastatic site had responded strongly to chemotherapy even though the overall disease ultimately remained life-limiting.
Where this story comes from
This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full
How we source and attribute stories Accuracy and limitations
Collections this story belongs to
- Stage 4 Lung Cancer 384 stories
- Carboplatin for Stage 4 Lung Cancer 104 stories
- Carboplatin for Lung Cancer 168 stories
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer